The ready ability to demonstrate the functional and structural properties of tumor cells at the light and electron microscopic level using immunocytochemical techniques on conventionally prepared material has proved to be a most valuable technical advance. Again, CEA had a part to play, although some peptide hormones and enzymes had been demonstrated in this way for at least the prior decade. The availability of monoclonal antibodies to a wide range of tumor cellassociated moieties has obviously given further impetus to such research. In clinical terms, such immune probes may have not only radioimmunodiagnostic and immunotherapeutic roles but also assist through immunocytochemistry in the readier morphological detection of small foci and/or minimal numbers of cancer cells. This latter approach using diverse probes has been shown to have value in the detection of micrometastases in lymph nodes and the bone marrow. On p. 101 of this issue, a study of tumor-associated pleural effusions showed the increased value of antibody staining which resulted in a significantly improved detection rate in effusions where no malignant cells were seen by conventional morphology. This editorial posed a question. The present commentator believes that the answer is most certainly in the affirmative.
